EUCTR2005-001290-10-IT进行中（未招募）不适用
A study to provide expanded access of Exjade deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with other locally approved iron chelators.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 3,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A study to provide expanded access of EXJADE (deferasirox) to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with other locally approved iron chelators.Chronic iron overload from blood transfusions in patients with congenital disorders of red blood cellsEUCTR2005-001290-10-GRovartis Pharma Services AG3,000
进行中（未招募）
不适用
A study to provide expanded access of EXJADE® (deferasirox) to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with other locally approved iron chelatorsChronic iron overload from blood transfusions in patients with congenital disorders of red blood cellsEUCTR2005-001290-10-DEovartis Pharma Services AG3,000
进行中（未招募）
不适用
A study to provide expanded access of EXJADE® (deferasirox) to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with other locally approved iron chelatorsChronic iron overload from blood transfusions in patients with congenital disorders of red blood cellsEUCTR2005-001290-10-BEovartis Pharma Services AG3,000
进行中（未招募）
1 期
A study to provide expanded access of EXJADE® (deferasirox) to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with other locally approved iron chelatorsChronic iron overload from blood transfusions in patients with congenital disorders of red blood cellsEUCTR2005-001290-10-IEovartis Pharma Services AG
进行中（未招募）
1 期
A study to provide expanded access of EXJADE® (deferasirox) to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with other locally approved iron chelatorsChronic iron overload from blood transfusions in patients with congenital disorders of red blood cellsEUCTR2005-001290-10-GBovartis Pharma Services AG